GRANTS
National Institutes of Health (NIH):
Oral Dissolvable Strips (ODS) as new pediatric and adult delivery mode of therapy for latent TB (1R43AI179391-01)
National Institute of Allergy and Infectious Diseases (NIAID):
Novel antiretroviral therapy delivery platform for infants & young children - oral dispensable strips (1R43AI170237-01)
National Institute of Allergy and Infectious Diseases (NIAD):
Oral Dissolving Strips for the Delivery of Isoniazid in Children and Adults for the treatment of TB (HHSN272201600033C)
University of Kansas:
Prophylactic Oral Dissolvable Strips of Antiretroviral (ARV) medications to minimize infant’s risk of HIV acquisition during breastfeeding.
AWARDS
California Central Coast Innovation Award (2016):
Category Biomedicine
Angelini Pharma Innovation Award (2024):
“Transforming Epilepsy Treatment Adherence through Innovative Oral Dissolvable Strip Technology”
INTELLECTUAL PROPERTY
Oral Delivery of Drug Actives in Laboratory Animals using Fast Dissolving Films
(US 20150366998A)
Multi-layered High Dosage Film for Oral Administration
(US 11,185,500)
Long-Acting Continuous Oral Release from Oral Dispersing Strips (ODS) Addressing the Need for High Dosage Active Ingredients
(In Preparation)
Trade Secrets
Related to computational formulation for rapid ODS development as well as continuous manufacturing
